Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.30 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL14745544 | 0.87 | PARP1 (0.33) | PDE3BPDE3APARP1PARP2CACNA1B | |
| Trifluoroacetic Acid SCHEMBL14745542 | 0.87 | PARP1 (0.33) | PDE3BPDE3APARP1PARP2CACNA1B | |
| Trifluoroacetic Acid SCHEMBL16568516 | 0.87 | PARP1 (0.33) | PDE3BPDE3APARP1PARP2CACNA1B | |
| SCHEMBL17594883 | 0.85 | PARP1 (0.35) | PDE3BPDE3APARP1PARP2 | |
| SCHEMBL16577238 | 0.85 | PARP1 (0.35) | PDE3BPDE3APARP1PARP2 | |
| SCHEMBL17594885 | 0.85 | PARP1 (0.35) | PDE3BPDE3APARP1PARP2 | |
| SCHEMBL17594875 | 0.85 | CACNA1B (0.38) | PDE3BPDE3APARP1PARP2CACNA1B | |
| SCHEMBL14745507 | 0.84 | PIK3CA (0.31) | — | |
| SCHEMBL14744863 | 0.83 | HRH3 (0.41) | — | |
| SCHEMBL14745082 | 0.83 | CACNA1B (0.35) | PARP1PARP2CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016039936-A2 | MONOCYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | claimed |
| US-9650395-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2750505-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033240-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | PDE3B 2942/4885PDE3A 2531/4885PARP1 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.